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Background
Persistent stimulation of nociceptors results in sensitiza-
tion of nociceptive sensory neurons, which is associated
with hyperalgesia and allodynia. The release of NO and
subsequent synthesis of cGMP in the spinal cord are
involved in this process. cGMP-dependent protein kinase
I (PKG-I) has been suggested to act as a downstream target
of cGMP, but its exact role in nociception hadn't been
characterized yet. To further evaluate the NO/cGMP/PKG-
I pathway in nociception we assessed the effects of PKG-I
inhibiton and activaton in the rat formalin assay and ana-
lyzed the nociceptive behavior of PKG-I-/- mice.
Results
The PKG-I-inhibitor, Rp-8-Br-cGMPS (0.1 – 0.5 µmol i.t.),
reduced the nociceptive behaviour of rats in the formalin
assay [1]. In contrast, administration of a high dose (2.5
µmol i.t.) of the cGMP analogue, 8-Br-cGMP, caused
hyperalgesia. However, low doses of the same drug (0.1 –
0.25  µmol i.t.) unexpectedly reduced the nociceptive
behaviour, revealing dose-dependent contrary effects of 8-
Br-cGMP. The antinociceptive effects of 'low-dose' 8-Br-
cGMP are obviously independent of PKG-I activation,
since co-administration with the PKG-I inhibitor, Rp-8-
Br-cGMPS, failed to antagonize antinociception [2]. To
further assess the role of PKG-I in nociception, we studied
the behaviour of PKG-I-/- mice. PKG-I deficiency was asso-
ciated with reduced nociceptive behaviour in the formalin
assay and reduced mechanical hyperalgesia during
zymosan-induced paw inflammation. A high dose of 8-Br-
cGMP (250 nmol i.t.) caused mechanical allodynia only
in PKG-I+/+ mice, indicating that the presence of PKG-I
was essential for this pronociceptive effect. In contrast,
administration of 'low-dose' 8-Br-cGMP (25 nmol i.t.)
reduced the nociceptive behaviour in both PKG-I+/+ and
PKG-I-/- mice, supporting the hypothesis that the antinoc-
iceptive effects of 8-Br-cGMP are independent of PKG-I
activation [3].
Conclusions
Our data suggest that in the spinal cord, high concentra-
tions of cGMP cause hyperalgesia through activation of
PKG-I, whereas low concentrations of cGMP reveal anti-
nociceptive effects via a PKG-I-independent mechanism.
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